๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

17 recruiting trials

for Non-segmental Vitiligo

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients NCT06991972Phase 41 site๐Ÿ“ Peshawar Khyber Teaching Hospital ยท Tests: Needling + NBUVB, Microneedling + NBUVB A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa NCT07136467n/a116 sites๐Ÿ“ Ciudad Autonoma de Buenos Aire๐Ÿ“ Buenos Aires๐Ÿ“ Buenos Aires AbbVie Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo NCT07172347Phase 21 site๐Ÿ“ Beijing Jiangsu vcare pharmaceutical technology co., LTD ยท Tests: VC005 tablets, VC005 Tablets Placebo A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo NCT07889492Phase 24 sites๐Ÿ“ Edmonton๐Ÿ“ Guelph๐Ÿ“ Newmarket Edesa Biotech Inc. ยท Tests: Placebo IV, EB06 An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) NCT07105254Phase 21 site๐Ÿ“ Dallas Derm Texas, PLLC ยท Tests: Roflumilast topical 0.3% foam A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo NCT07682506Phase 31 site๐Ÿ“ Beijing Minghui Pharmaceutical (Hangzhou) Ltd ยท Tests: MH004 1.0% Ointment, MH004 Placebo Ointment A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo NCT07533019Phase 235 sites๐Ÿ“ Phoenix๐Ÿ“ Phoenix๐Ÿ“ Fremont Eli Lilly and Company ยท Tests: LY4005130, Placebo Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus NCT06719024Phase 2, Phase 31 site๐Ÿ“ Hong Kong Hospital Authority, Hong Kong ยท Tests: Ruxolitinib Cream 1.5%, Aqueous cream A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo NCT07251595Phase 21 site๐Ÿ“ Jinan Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR0302 Tablets, SHR0302 Base Gel, SHR0302 Placebo Tablets, SHR0302 Base Placebo Gel Study of D-2570 in Subjects With Non-Segmental Vitiligo NCT07625891Phase 21 site๐Ÿ“ Shanghai InventisBio Co., Ltd ยท Tests: D-2570 Dose 1, D-2570 Dose 2, Placebo, D-2570 Dose 3 Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration NCT07554222Phase 11 site๐Ÿ“ Shanghai Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: placebo, Baricitinib tablets, IBI3013 ICP-332 in Subjects With Non-segmental Vitiligo NCT07047612Phase 2, Phase 345 sites๐Ÿ“ Wuhu๐Ÿ“ Wuhu๐Ÿ“ Beijing Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: ICP-332 Tablets, ICP-332 Placebo Tablets Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study NCT07673640n/a20 sites๐Ÿ“ Shenzhen๐Ÿ“ Huai'an๐Ÿ“ Suzhou ShanShan Li ยท Tests: 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients NCT07223229Phase 26 sites๐Ÿ“ Huntington Beach๐Ÿ“ Hollywood๐Ÿ“ Worcester Elixiron Immunotherapeutics (Hong Kong) Ltd. ยท Tests: EI-001, Placebo A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo NCT07357870Phase 12 sites๐Ÿ“ Ankara๐Ÿ“ Istanbul CAGE Bio Inc. ยท Tests: Drug: CGB-600 gel, experimental drug, placebo: gel vehicle A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo NCT07431177Phase 283 sites๐Ÿ“ Birmingham๐Ÿ“ Fountain Valley๐Ÿ“ San Diego Novartis Pharmaceuticals ยท Tests: GIA632, Placebo A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo NCT07712523Phase 21 site๐Ÿ“ Shenyang E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. ยท Tests: QY201 Tablets(5mg๏ผ‰, QY201 Tablets๏ผˆ10mg๏ผ‰, QY201 Tablets๏ผˆ20mg๏ผ‰, QY201 Placebo Tablets
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy